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DYNAMICS OF RECOVERY IN DOUBLE UMBILICAL CORD BLOOD TRANS-
PLANTATIONWITH AN EX-VIVO MESENCHYMAL CELL EXPANDED UNIT:
FASTER RECOVERY WITH ENGRAFTMENT OF THE EXPANDED UNIT
Saliba, R.M.1, de Lima, M.1, McMannis, J.-, Robinson, S.1, Shpall, E.1,
Champlin, R.E.1, Bosque, D.M.1, Parmar, S.1, Rondon, G.1,
Simmons, P.2, Alousi, A.1 1The University of Texas MDAnderson Cancer
Center; 2The University of Texas Health Science Center, Houston
Double cord blood transplantation (CBT) with ex-vivo expansion
aims at overcoming the delayed engraftment frequently observed af-
ter CBT. Thirty-one patients received myeloablative therapy with
melphalan, fludarabine, thiotepa and ATG followed by double
CBT for treatment of hematologic malignancies. One of the 2 units
was expanded (exp) ex-vivo in a co-culture with either third party
haploidentical family member marrow derived mesecnchyal stem
cells (N5 8) or off-the-shelf mesenchymal progenitor cells fromAn-
gioblast (N 5 23). Both CB units were matched in at least 4/6 HLA
antigens with the patient, and contained a minimum of 1x107 TNC/
Kg per unit. The majority of patients (pts) received CBT for treat-
ment of acute leukemia including AML / MDS (64%) and ALL
(19%), and 42% were in remission at CBT.Median age was 36 years
(range 2.8-62). The non-exp unit was matched with the pt in 6/6
HLA antigens in 3%, 5/6 in 26% and 4/6 in 71% of cases; the cor-
responding distribution for the exp unit was 6%, 29%, 64%. En-
graftment was documented in 29 evaluable pts at a median of 15
(range 9 to 42) days for neutrophils and 40 (range 18 to 62) days
for platelets. Day 30 chimerism showed evidence of engraftment of
the non-exp unit only in 15 (52%) pts, and of both units in 13
(45%) pts, including 9 and 4 in whom the non-exp and the exp
unit dominated, respectively. Chimerism was undetermined in 1
pt. Comparison of the rate of recovery in pts who had (N 5 13)
and those who did not have (N 5 15) evidence of engraftment of
the exp unit showed that neutrophils and platelet recovery was faster
when the exp unit engrafted (median of 15 vs. 19 days for neutrophils;
and 38 vs. 40 days for platelet). This difference did not reach statis-
tical significance however. The median numbers of TNC and
CD34+ cells infused/Kg were significantly higher in the engrafted
exp than in the non-engrafted exp unit (p\0.05). Sixteen pts were di-
agnosed with grade II-IV aGVHD including 12 within 100 days post
CBT.GVHDwas severe (grade III-IV) in 5 pts.Onunivariate analysis,
there was a trend for a higher 6 month rate of grade II-IV aGVHD
when the exp unit engrafted (cumulative incidence (CI) 65% vs
49%, P 5 0.2); when the non-exp unit was only 4/6 HLA matched
with the pt (CI 65% vs 25%), p 5 0.2; and when CMV serostatus
was reactive in both the recipient and in the non-exp unit (CI 77%
vs 35%, p 5 0.1). The investigation of CB expansion is warranted in
a larger study population and accrual to our study continues.
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AN INSTITUTIONAL EXPERIENCE OF ADVERSE EFFECTS IN PATIENTS OF
ADVANCED AGE USING CYCLOSPORINE AND MYCOPHENOLATE
MOFETIL FOR GRAFT VERSUS HOST DISEASE PROPHYLAXIS IN REDUCED
INTENSITY CONDITIONED TRANSPLANT
Allen, B.E.1, Tyler, K.B.2 1Oregon Health and Science University, Port-
land, OR; 2Oregon Health and Science University, Portland, OR
Hematopoietic cell transplant in those with advanced age and/or
with a higher number of co-morbid factors is a viable treatment option
in this new era of reduced intensity conditioning (RIC) (McClune, et
al, 2010; JCO, 2010). Based on the intensity of conditioning, RIC
transplantation may require a greater degree of immune suppression
to decrease the risk of graft rejection. However, greater efficacy may
be counter balanced bymore toxicity, particularly in older patient pop-
ulations for whom these treatments are being developed. For fludara-
bine/TBI 200cGy conditioning with cyclosporine (CSA) and
mycophenolate mofetil (MMF) graft versus host disease (GvHD) pro-
phylaxis, CSAdosing is targeted at levels of 500-600ng/mL. In this set-
ting, 12% of patients (median age 54) undergoing RIC procedures
with these conditions experienced grade 3-5 nephrotoxicity, as defined
by the NCI CTC (Diaconescu, et al, Blood, 2004). These toxicities
may be even more highly accentuated in older patients. To better ap-
preciate the prevalence and severity of adverse effects related to CSA
exposure, we analyzed data from 91 patients over age 60 undergoing
RIC transplant at our institution from 2001 – 2010 who received
CSA/MMF GvHD prophylaxis.Our research found numerous CSA related adverse effects includ-
ing: electrolyte imbalances (100%) (hypomagnesia, hypokalemia and
hyperkalemia); nephrotoxicity (88%); neurotoxicity (12%) including
PRES and tremor; musculoskeletal effects in particular weakness
(11%); cardiovascular impacts from CSA induced hypertension
(53%) and hematologic toxicity from micro-angiopathic hemolytic
anemia (1%).
The above described toxicities associated with CSA are well-
known, yet in our review of this cohort of RIC transplants the inci-
dence of CSA related adverse events was pronounced. This level of
adverse events requires more aggressive monitoring and manage-
mentwhich leads to increased resource utilization ofmedical person-
nel and dollars, and may have a negative effect on patient outcomes.
In practice, we should continue to explore ways to optimize patient
care while controlling expense and resource utilization, and obtain
a greater understanding of the role that age and co-morbid factors
have on the transplant course given the expanding role of RIC. To
that end, we are currently comparing the rates of CSA-induced
complications in this cohort to a group of comparable patients un-
dergoing myeloablative transplant.
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L-LEUCYL-L-LEUCINE METHYL ESTER (LLME) TREATED NON-MYELOA-
BLATIVE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
(HSCT) FOR PATIENTS WITH HEMATOLOGICAL MALIGNANCIES
Wagner, J.L., Grosso, D.A., Brunner, J., Carabasi, M.A., Filicko-
O’Hara, J.E., Mookerjee, B., Flomenberg, N. Thomas Jefferson
University, Philadelphia, PA
GVHDremains an obstacle for allogeneicHSCT.While T cell de-
pletion of donor grafts results in much lower incidences of GVHD,
rejection and poor immune recovery are often associated with this ap-
proach. To address these issues, we developed a transplant approach
using LLME to test the hypothesis that the selected depletion of T
cells containing cytotoxic effector granules would result in less signif-
icant GVHD while at the same time preserving GVT effects and in-
fectious immunity. LLME preferentially kills cytotoxic effector
granule bearing lymphocytes including most NK and CD8 T cells
with relative sparing of CD4T cells. Fourteen patients, with a median
age of 57 years with high risk disease were transplanted from related or
unrelated donors after a conditioning regimen of flu/cyclo/ara-C.
Prior to the infusion of the donor inoculum, we performed CD34 se-
lection using the Isolex system to separate the graft into CD34+ and
CD34- fractions. TheCD34- fractionwas then treatedwithLLME to
selectively deplete the cytotoxic effector granule containing subsets,
thus avoiding stem cell exposure to LLME. Patients received the
CD34 selected stem cell product (median CD34 dose 4.13 x 106/
kg). This HSC product contained 5 x 104 untreated CD3 cells/kg in
the initial 6 patients treated, but due to significant GVHD, the final
8 patients received 2.5 x 104 untreated CD3 cells/kg. One day later,
the LLME treated CD34- fraction (median CD3 dose 8.74 x106
/kg) was infused. One patient died shortly after the stem cell infusion
from infectious complications. All 13 evaluable patients engrafted
WBCby day 14.Two patients experienced late rejection.One of these
patients is still alive 3 years later with evidence of recurrent disease and
the other patient eventually died of relapsed disease. Of the remaining
11 patients, 3 patients developed grade III-IV GVHD and 1 patient
developed cGVHD. All 4 of these patients died of GVHD related
causes. Three patients died of complications from relapsed disease
and 1 additional patient died of infectious complications. Four pa-
tients are alive at a minimum of 3 years post transplant. Two of these
patients have relapsed disease, 1 patient is disease free with 100% do-
nor chimerism and one patient is disease free with a persistence of 5%
host cells. This study shows that LLME can be used to treat lympho-
cytes without affecting initial engraftment, but relapse and GVHD
remain significant barriers in this high risk population.
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MELPHALAN AND TOTAL-BODY IRRADIATION (MEL-TBI) IS AN EFFEC-
TIVE CONDITIONING REGIMEN FOR ALLOGENEIC STEM CELL TRANS-
PLANTATION (ALLO-SCT) IN PATIENTS WITH VERY POOR-RISK
REFRACTORY HEMATOLOGIC MALIGNANCIES
Akpek, G., Marangoz, D., Ilyas, C., Akbulut, V., Bhatnagar, B.,
Ruehle, K., Badros, A.Z., Yanovich, S., Rapoport, A.P. University of
Maryland Medical Center, Baltimore, MD
Poster Session II S319Introduction:Transplant outcome is poor in patients with advanced
hematologic malignancies that are not in remission. We evaluated
the safety and efficacy of a preparative regimen consisting of frac-
tionated TBI (12 Gy) and MEL (100 mg/m2 in a single dose) in 26
adult patients with refractory/relapsed AML (n 5 11), ALL (n 5
5), NHL (n 5 5), and other malignancies (n 5 5) who received
allo-SCT between 2003 and 2008.
Patients and Methods:Median age was 49 (21 to 68) years and the
median time from initial diagnosis to allo-SCT was 12.8 months
(range, 2.3 to 58.8 months). Five patients had prior autologous
SCT and 3 had prior allo-SCT. At the time of transplant, 15
(58%) had poor-risk complex cytogenetics, 10 out of 16 acute leuke-
mia patients (63%) had circulating blasts. The stem cell product was
T-cell replete in all but one patient. Thirteen patients (50%) re-
ceived 8/8 matched MUD allo-SCT, 3 of whom were mismatched
at one antigen or allele level. Four patients received a bone marrow
product. Tacrolimus6 low dose methotrexate were used as GVHD
prophylaxis in the majority of patients.
Results: One patient died on day +7 after SCT. The remaining 25
patients achieved hematopoietic engraftment with no significant de-
lay. Treatment-related toxicity was moderate and consisted mainly
of mucositis, infections and pulmonary complications such as
CMV pneumonitis and diffuse alveolar hemorrhage. Three addi-
tional patients died early after SCT on days +32, +40 and +50. Me-
dian duration of hospitalization was 29 days (range, 14 to 97). Of
23 evaluable patients, 13 (57%) achieved complete remission (CR)
and 7 had partial remission. Three patients had no response to trans-
plant. Fourteen patients relapsed at a median time of 166 days (range
33-1548) after allo-SCT.Median overall survival of the entire group
was 159 days. The 3-year Kaplan-Meier estimate of survival for all 26
patients was 16%. One AML patient relapsed with a different clone
after remaining in CR for 4.9 years. Two patients are currently alive
and in CR at 995 and 1320 days posttransplant.
Conclusions: Our early data suggest that, TBI-MEL is an active
preparative regimen against acute leukemia and perhaps other ad-
vanced hematologic malignancies that are not in remission. Regi-
men-related toxicity is acceptable and relapse is the most common
cause of treatment failure. A comparative analysis in a larger data-
set is warranted to further evaluate the efficacy and safety of TB-
MEL in such high-risk patients.
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SERUM FERRITIN IS A POTENTIAL PROGNOSTIC MARKER FOR TREAT-
MENT-RELATED MORTALITY AND OVERALL SURVIVAL IN ALLOGENEIC
HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENTS IN TAI-
WAN
Ko, B.-S.1, Yao, M.1, Lu, M.-Y.2, Lin, K.-H.2, Li, C.-C.3, Lin, C.-T.3,
Chen, Y.-C.4, Tang, J.-L.1 1National Taiwan University Hospital,
Taipei, Taiwan, Taiwan; 2National Taiwan University Hospital, Taipei,
Taiwan, Taiwan; 3National Taiwan University, Taipei, Taiwan,
Taiwan; 4National Taiwan University Hospital, Taipei, Taiwan, Taiwan
In the past years, the roles of iron overloading in allogeneic hema-
topoietic stem trasnplnatation (allo-HSCT) had been discussed. Sev-
eral articles indicated that high serum ferritin level was a poor
prognostic marker, but this was not validated in Chinese population.
We then established a cohort of 101 patients who received allo-
HSCT in our hospital, one of the largest in Taiwan, from Jan,
2008 to Jul, 2010, and try to find if serum ferritin has any prognostic
significance for them.Theirmedian age was 32 y/o (0-61 y/o). Serum
ferritin was all checked within one month before allo-HSCT (me-
dian 1692 mg/dl, ranging from 56 to 23026 mg/dl), and patients
were grouped to high ferrtin group (ferritin . 1500 ng/ml, N 5
56) and low ferritin group (ferritin # 1500 mg/dl, N 5 45) accord-
ingly. Table 1 summerized the baseline characters of these 2 patient
groups. Almost all parameters were comparable, except that there
were a little more acute lymphoblastic leukemia patients in the low
ferritin group. After tranplant, the engraftment kinetics in high fer-
ritin group were comparable as those in low ferritin group (neutro-
phil recovery (ANC $ 0.5x109/L) 13.063.2 vs 13.666.7 days;
platelet recovery ($ 50x109/L) 25.6610.8 vs 28.6612.7 day). The
incidences of acute GVHD were also comparable (22/17 vs 18/20,
p 5 0.45). However, trends of increased 1-year treatment-related
mortality were observed in high ferritin group (26.267.8% vs
14.964.8%, p 5 0.064) and then 1-year overall survival was signifi-cantly compromised in high ferritin group (62.868.5% vs
79.265.8%, p 5 0.033). Relapse-free survival in high ferritin group
seemed to be lower, but not yet statistically different from that in
low-ferritin group (55.4612.4% vs 83.764.8%, p 5 0.113). From
this analysis, we can conclude that in Chinese population, patients
with serum ferritin$ 1500 mg/dl are at higher risk of treatment-re-
lated mortality and compromised overall survival when they receive
allo-HSCT. However, because serum ferrtin not only is affected by
body iron store but also is an indicator of systemic inflammation,
whether iron cheletion therapy would benifit these patients remains
unknown andwell-designed prospective clinical trials are still needed
for the answer.
Table 1. Comparison of the baseline characters of patients
with serum level#1500mg/dL and >1500mg/dL
Ferritin#1500mg/dL Ferritin>1500mg/dLPatient number 45 56
Age 26(0-61) 29(2-61)
Sex(M/F) 24/21 30/26
Cell Source
BM/PB/UCB 10/34/1 8/46/2
Donor
Sibling/Unrelated 31/15 34/22
Diagnosis
AML/ALL/CML 12/12/2 25/7/1
MPD or MDS 5 8
Lymphoma 7 4
Others 7 11
MNC(x10^8/Kg) 9.30 ± 7.39 9.57 ± 6.55
CD34+(x10^6/Kg) 5.67 ± 3.90 5.81 ± 4.24
Conditioning regimens
BuCy+/2ATG 17 19
TBI+Cy+/2ATG 8 8
F+Bu2y1+/2ATG 8 17
F+TBI+/2ATG 1 4
Others 11 8ATG, anti-thymocyte globulin; F, fludarbine; TBI, total body irradiation;
UCB, umbilical cord blood.
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DECITABINE AS A BRIDGING THERAPY BEFORE ALLOGENEIC STEM CELL
TRANSPLANTATION FOR MYELODYSPLASTIC SYNDROME
Jang, J.H.1, Kim, D.-Y.2, Kim, D.H.1, Kim, K.1, Lee, J.-H.2, Lee, K.-
H.2, Jung, C.W.1, Lee, J.-H.2 1SamsungMedical Center, Sungkyunkwan
University School of Medicine, Seoul, Korea; 2Asan Medical Center, Uni-
versity of Ulsan College of Medicine, Seoul, Korea
Decitabine is effective for myelodysplastic syndrome but is not cu-
rative. The only curative treatment is allogeneic stem cell transplanta-
tion(allo-SCT). There were few reports about pretransplant use of
decitabine as a bridging therapy. We report 18 patients (median age
47, range 40-55 years, male 11, female 7) with MDS (9 patients were
in IPSS Int-1, 6 patients in Int-2, and 3 patients in IPSS high) who
all received at least 3 cycles of decitabine (median 4 cycles, range
38 cycles) and subsequent allo-SCT(from sibling donor in 5 patients,
unrelated donor in 13). Conditioning regimens consisted of FluBu46
ATGor low doseTBI400cGy (n5 8), FluBu2/ATG (n5 7), BuCY6
ATG (n5 2), or TBI/CY/ATG (n5 1). The source of stem cells was
marrow in 1 patients and peripheral blood in 17 patients. Successful
leukocyte engraftment was attained in 17/18 patients (median 12
days, range 917 days). Platelet engraftment was attained in 15/18 pa-
tients (median 15 days, range 1131 days). Grade IIIV skin acute
GVHD were in 5/18 patients, liver or gut acute GVHD in 1/18 pa-
tients. 14/18 patients achieved a CR at 30 days after transplant. Grade
IIIV chronic GVHD were in 10 patients. With a median follow-up
of 18 months (range, 628 months), 11 patients are alive with CR. 7
patients have died either from relapse (n 5 3) or treatment related
complications (n5 4).Responders to decitabinebefore transplantation
tend to have a better survival than non-responders. We conclude that
pretransplant use of decitabine is feasible, with no increased toxicity
and tend to improve the outcome of allo-SCT for MDS and should
be evaluated in a prospective trial.
